Bioimpedance-guided fluid management for decompensated heart failure
Official title: Bioimpedance Integration for Optimized Fluid Management in Decompensated Heart Failure
Run by Mid and South Essex NHS Foundation Trust · NCT07173426 · Data updated 2026-11-12
This test sees if using bedside bioimpedance measurements to guide diuretic treatment helps people hospitalized with worsening heart failure manage fluid and reduce extra treatment or rehospitalization within 90 days.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 255 (estimated) |
| Sponsor | Mid and South Essex NHS Foundation Trust Academic / other |
| Locations | 1 site (Basildon, Essex) |
| Status | Recruiting |
| Started | December 30, 2024 |
| Main results expected | May 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT07173426 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) admitted to hospital with a decompensated episode of heart failure who can give informed consent and are not in intensive care, on renal replacement therapy, or on a palliative pathway are the ideal candidates.
✕Probably not a fit
Patients on renal replacement therapy, those receiving intensive care, those on a palliative care pathway with limited life expectancy, or those already in other interventional heart failure trials are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Hospitalized adults with decompensated heart failure are randomly assigned to either a group where bioimpedance analysis (BIA) is used serially to guide diuretic therapy or a standard care group where BIA is measured but not shared with the clinical team. The BIA-guided group receives measurements within 24 hours of admission and throughout the hospital stay to inform fluid management decisions, while the control group follows usual clinical assessment. The main outcome is whether BIA guidance reduces the need for additional diuretic treatment or rehospitalization for heart failure within 90 days after discharge. The trial is conducted at Basildon University Hospital and excludes patients on renal replacement therapy, in intensive care, on palliative pathways, or enrolled in other interventional heart failure trials.
Why it matters
Potential benefit: If successful, this approach could reduce repeat hospital admissions and unnecessary extra diuretic treatments by improving bedside fluid management.
How similar studies have gone: Smaller prior studies have suggested BIA-guided therapy can improve fluid management and lower biomarkers like NT-proBNP, but large randomized evidence in hospitalized decompensated heart failure is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years 2. Patients with hospitalised with a decompensated episode of Heart Failure regardless of Ejection Fraction 3. Able and willing to consent. Exclusion Criteria: 1. Patients on a palliative care pathway and/or estimated life expectancy \<3 months 2. Patients admitted to ITU/ on intensive care support. 3. Patients currently taking part in any trials investigating new heart failure drug or interventional treatment. 4. Patients requiring Renal Replacement Therapy. 5. Patients unable or unwilling to give consent.
Where it's running
-
Basildon University Hospital
Basildon, Essex, United Kingdom Recruiting
Study contacts
- Study coordinator: Henry Oluwasefunmi Savage, MD FRCP
- Email: henry.savage@nhs.net
- Phone: +44 01268524900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using BIOMONITOR IV to track heart rhythm and warning signs in people with heart failure
This project will test whether a small implanted monitor called BIOMONITOR IV can track irregular heartbeats and body signals in people with heart failure who do not have ICD/CRT devices to see if it can warn doctors before the heart failure gets worse.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Using a new device to monitor heart pressure in patients recovering from heart failure
This study is testing a new device that measures heart pressure in patients recovering from heart failure to see if it can help doctors predict who might get worse and improve their care.
-
Using colchicine to treat acutely decompensated heart failure with reduced ejection fraction
This study is testing if colchicine, an anti-inflammatory medication, can help people in the hospital with heart failure feel better and improve their heart function.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.